Xanodyne Pharmaceuticals, Inc.
|Xanodyne Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20100280117||Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders - Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders.||11-04-2010|
|20100203160||Vitamin/Mineral Composition with DHA - Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.||08-12-2010|
|20100143468||Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.||06-10-2010|
|20090215898||TRANEXAMIC ACID FORMULATIONS - Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.||08-27-2009|
|20090214644||TRANEXAMIC ACID FORMULATIONS WITH REDUCED ADVERSE EFFECTS - Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.||08-27-2009|
|20090209646||TRANEXAMIC ACID FORMULATIONS - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.||08-20-2009|
|20090048341||Tranexamic acid formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.||02-19-2009|
|20090017114||Tranexamic acid formulations with reduced adverse effects - Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.||01-15-2009|
|20080280981||Tranexamic acid formulations - Disclosed are oral tranexamic acid formulations and methods of treatment therewith.||11-13-2008|
Patent applications by Xanodyne Pharmaceuticals, Inc.